ADHD: What Parents Need to Know
MONDAY, Sept. 4, 2023 -- Lots of children and adolescents have the condition known as ADHD, or attention-deficit/hyperactivity disorder.
What should parents know? A number of treatments exist to help with functioning, including medications approved... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - September 4, 2023 Category: General Medicine Source Type: news
Generic Drugmakers Start Shipping Copies of ADHD Drug Generic Drugmakers Start Shipping Copies of ADHD Drug
Drugmakers have begun shipping copycat versions of Takeda Pharmaceutical ' s drug Vyvanse, which is expected to offset the ongoing shortage of the ADHD medicine in the United States.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 1, 2023 Category: Consumer Health News Tags: Psychiatry News Source Type: news
ADHD drug Ritalin could wean America's 5million cocaine users off the powder, study suggests
Researchers at the University of Virginia say animal studies have shown Ritalin (pictured) triggers reduced dependence on the white powder, although results are mixed in humans. (Source: the Mail online | Health)
Source: the Mail online | Health - August 31, 2023 Category: Consumer Health News Source Type: news
Mallinckrodt Receives U.S. FDA Approval for Lisdexamfetamine Dimesylate Capsules and Launches Product Used to Treat Attention-Deficit/Hyperactivity Disorder (ADHD)
DUBLIN, Aug. 31, 2023 -- (Healthcare Sales & Marketing Network) -- Mallinckrodt plc (OTCMKTS: MNKTQ), a global specialty pharmaceutical company, today announced that its Specialty Generics segment, operating as SpecGx LLC, received approval on August 25, ... Biopharmaceuticals, Generics, FDA Mallinckrodt, SpecGx, lisdexamfetamine, ADHD (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 31, 2023 Category: Pharmaceuticals Source Type: news
Systematic review of environmental and psychosocial risk factors associated with attention deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder in children and adolescents - Elbagir R, Faisal M, O'Hanharan S.
BACKGROUND: In the majority of cases, attention deficit hyperactivity disorder (ADHD) is accompanied by one or more comorbid disorders, with the oppositional defiant disorder (ODD) being one of the most frequently diagnosed comorbid disorders. There is a l... (Source: SafetyLit)
Source: SafetyLit - August 31, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
On Money, ADHD Diagnosis Can Be Revelatory
After racking up $15,000 in debt, Ellyce Fulmore was diagnosed with A.D.H.D. in December 2020.Credit...Todd Korol for The New York Times A diagnosis of attention deficit hyperactivity disorder in adulthood has solved a mystery for some women, helping them get control over their finances. For Women…#ellycefulmore #adhd #toddkorol #dopamines #edwardmhallowell #hallowelladhdcenters #tiktok #nt #additude (Source: Reuters: Health)
Source: Reuters: Health - August 31, 2023 Category: Consumer Health News Source Type: news
FDA OKs ADHD Generics; Flotation Therapy; Civilians Respond to Distress Calls
(MedPage Today) -- The FDA approved the first generic forms of lisdexamfetamine dimesylate (Vyvanse) capsules and chewables to treat attention deficit-hyperactivity disorder (ADHD) in patients 6 years and older, as well as moderate to severe binge... (Source: MedPage Today Psychiatry)
Source: MedPage Today Psychiatry - August 30, 2023 Category: Psychiatry Source Type: news
Vaccine Skepticism Spreads to Pets; Generics for ADHD Approved; Malaria in Maryland
(MedPage Today) -- Note that some links may require registration or subscription.
Some dog owners questioned pet vaccines like rabies, survey data showed. (Vaccine)
The FDA approved multiple generics of lisdexamfetamine dimesylate to treat attention... (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - August 29, 2023 Category: Pediatrics Source Type: news
Generics of Vyvanse, Takeda's ADHD drug, get FDA green light
Takeda Pharmaceutical Company Limited just lost exclusivity on its ADHD drug. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 28, 2023 Category: Pharmaceuticals Authors: Rowan Walrath Source Type: news
FDA Approves First Generics for Vyvanse
August 28, 2023 -- FDA has approved several first generics of Vyvanse (lisdexamfetamine dimesylate) capsules and chewable tablets for attention-deficit/hyperactivity disorder (ADHD) in patients six years and older and moderate to severe binge-eating... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 28, 2023 Category: General Medicine Source Type: news
Risk factors of suicidal spectrum behaviors in adults and adolescents with attention-deficit / hyperactivity disorder - a systematic review - Austgulen A, Skram NKG, Haavik J, Lundervold AJ.
INTRODUCTION: Adolescents and adults with attention-deficit/hyperactivity disorder (ADHD) are at increased risk of suicidal spectrum behaviors (SSBs). However, there is limited knowledge about risk factors triggering SSBs in this group of people. O... (Source: SafetyLit)
Source: SafetyLit - August 26, 2023 Category: International Medicine & Public Health Tags: Research Methods, Surveillance and Codes, Models Source Type: news
La FDA informa cambios permanentes en el color de la piel relacionados con el uso del parche Daytrana (sistema transd érmico de metilfenidato) para el tratamiento del ADHD
[06-24-2015] La Administraci ón de Alimentos y Medicamentos (FDA) de los Estados Unidos advierte que el uso del parche Daytrana (sistema transdérmico de metilfenidato) para el tratamiento del Trastorno por Déficit de Atención e Hiperactividad (ADHD, por sus siglas en inglés) puede causar pérdida perm (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - August 25, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
6 Red Flags About the Mental-Health Content You ’ re Being Bombarded With on Social Media
The classic vision of therapy revolved around a person on a couch, supine, tapping into their deepest and darkest hopes and fears. A modern-day remix might look like this: a person still on a couch, but at home, scrolling through a constantly refreshing selection of mental-health content on social-media platforms like TikTok and Instagram.
Though it may feel therapeutic, experts advise proceeding with caution. As an increasing number of psychologists step into the role of mental-health influencer, opening the door to fame and financial incentives, their posts—on attachment styles or unresolved trauma or whatever e...
Source: TIME: Health - August 24, 2023 Category: Consumer Health News Authors: Angela Haupt Tags: Uncategorized healthscienceclimate Source Type: news
Treating and Dealing with ADHD
Studies show that the number of children diagnosed with attention-deficit/hyperactivity disorder (ADHD) continues to rise. The FDA has approved two types of medications – stimulants and non-stimulants – to help reduce the symptoms of ADHD and improve functioning in children as young as age 6. (Source: FDA Consumer Health Information Updates)
Source: FDA Consumer Health Information Updates - August 23, 2023 Category: Consumer Health News Authors: FDA Source Type: news
Understanding the causal relationships of attention-deficit/hyperactivity disorder with mental disorders and suicide attempt: a network Mendelian randomisation study - Meisinger C, Freuer D.
BACKGROUND: Attention-deficit/hyperactivity disorder (ADHD) is a lifespan neurodevelopmental condition resulting from complex interactions between genetic and environmental risk factors. There is evidence that ADHD is associated with other mental disorders... (Source: SafetyLit)
Source: SafetyLit - August 23, 2023 Category: International Medicine & Public Health Tags: Age: Adolescents Source Type: news
